The Latest Cardiac and Vascular News
PRINCETON, N.J., Aug. 2, 2022 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today reported unaudited financial and operating results for the quarter ended June 30, 2022. Second Quarter 2022 Financial Results Total Q2 […]
2022 Q2 quarterly HIGHLIGHTS compared to the corresponding period of 2021: Revenues were $14.8 million, an increase of 4%, compared to $14.3 million Net income was $4.1 million, or $0.60 per basic share and $0.51 per diluted share, compared to $6.7 million, or $1.00 per basic share and $0.83 per diluted share Cash and cash equivalents at June 30, 2022 increased to $40.0 million from $28.5 million SANTA […]
Regeneron’s press release reporting its second quarter 2022 results is also available on its media and investor relations website (http://newsroom.regeneron.com) Second quarter 2022 revenues decreased 44% to $2.86 billion versus second quarter 2021; excluding REGEN-COV®(a)(b), revenues increased 20% Second quarter 2022 EYLEA® U.S. net sales increased 14% versus second quarter 2021 to a […]
Company Received Final Positive Reimbursement Decision for VAZKEPA® by UK’s NICE in England & Wales Market Access Negotiations and Launch Preparations for VAZKEPA Underway Across Multiple European Markets Initiated Comprehensive Cost Reduction Plan in June to Address Market Dynamics in the U.S. with Expected Savings of $100 Million Over 12 Months* […]
Sotagliflozin New Drug Application for Heart Failure Accepted for Review by FDA, with PDUFA Action Date Anticipated in May 2023 LX9211 Phase 2 Clinical Proof-of-Concept Achieved in Painful Diabetic Neuropathy, Promising Novel Mechanism of Action in Neuropathic Pain Conference Call and Webcast at 5:00 pm Eastern Time THE WOODLANDS, Texas, […]
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second […]
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2022 financial results. “We delivered a remarkable second quarter as we continue changing the standard of care for millions of […]
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2022. Total revenues in the second quarter of 2022 grew 5% year-over-year to $466.9 million, compared to $446.5 million in the second […]
Accelerated Commercial Momentum to Achieve Net Revenue of $20.5 million 2022 Revenue Guidance Range Raised to $67 million to $75 million ANDOVER, Mass., Aug. 1, 2022 /PRNewswire/ — TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for […]
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 29, 2022 it granted stock options to purchase an aggregate of 88,200 shares of common stock to 11 new employees, whose employment commenced in July 2022, as a material inducement to […]
